SCHEMBL3390749

SCHEMBL3390749

COc1ccc(CC=O)cc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.62
CYP3A4 P08684 2/20 0.59
CYP1A2 P05177 1/20 0.59
TSHR P16473 1/20 0.59
NFKB1 P19838 1/20 0.59
ALOX15 P16050 1/20 0.59
ALOX12 P18054 1/20 0.59
ALDH1A1 P00352 2/20 0.58
AOX1 Q06278 1/20 0.58
MEN1 O00255 1/20 0.57
LMNA P02545 1/20 0.57
APEX1 P27695 1/20 0.57
KMT2A Q03164 1/20 0.57
TUBB4A P04350 4/20 0.56
TUBB P07437 4/20 0.56
TUBA3C P0DPH7 4/20 0.56
TUBA1B P68363 4/20 0.56
TUBA4A P68366 4/20 0.56
TUBB4B P68371 4/20 0.56
TUBB3 Q13509 4/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29520102 0.85 ALDH1A1 (0.72) GAACYP3A4TSHRNFKB1ALOX15
SCHEMBL917723 0.85 ALDH1A1 (0.72) GAACYP3A4TSHRNFKB1ALOX15
SCHEMBL909947 0.84 CYP1A2 (0.63) GAACYP3A4CYP1A2TSHRNFKB1
SCHEMBL30690114 0.84 CYP1A2 (0.63) GAACYP3A4CYP1A2TSHRNFKB1
Chavibetol SCHEMBL901503 0.84 ALOX5 (0.75) GAACYP3A4CYP1A2TSHRNFKB1
Chavibetol SCHEMBL29752081 0.84 ALOX5 (0.75) GAACYP3A4CYP1A2TSHRNFKB1
SCHEMBL30644304 0.82 ALDH1A1 (0.69) GAACYP3A4CYP1A2TSHRALDH1A1
SCHEMBL557409 0.82 ALDH1A1 (0.69) GAACYP3A4CYP1A2TSHRALDH1A1
SCHEMBL1360251 0.82 CYP3A4 (0.56) GAACYP3A4CYP1A2TSHRNFKB1
SCHEMBL620909 0.81 CYP1A2 (0.62) GAACYP3A4CYP1A2TSHRNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119306789-B Preparation method of Edwan sweet 山东奔月生物科技股份有限公司 2025-05-02 CN disclosed
CN-119306789-A Preparation method of Edwan sweet 山东奔月生物科技股份有限公司 2025-01-14 CN disclosed
WO-2024194018-A1 METHOD FOR PRODUCING CORYTUBERINE AND SALUTARIDINE Universität Graz (AT) 2024-09-26 WO disclosed
EP-4431612-A1 PROCESS FOR THE PREPARATION OF CORORYLOURIN AND SALUTARIDINE Universität Graz (AT) 2024-09-18 EP disclosed
CN-116535304-B Erianin analogue, and synthetic method and application thereof 中国科学院成都生物研究所 2024-07-19 CN disclosed
CN-116535304-A Erianin analogue, and synthetic method and application thereof 中国科学院成都生物研究所 2023-08-04 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3215152-A1 SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) The University of Kansas (US) 2017-09-13 EP disclosed
US-9745280-B2 Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient SNU R&DB FOUNDATION (KR) 2017-08-29 US disclosed
WO-2014130582-A2 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. (US) 2014-08-28 WO disclosed
WO-2012125533-A1 3-BENZYLOXYPHENYLOXOACETIC ACID COMPOUNDS FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2012-09-20 WO disclosed
WO-2012075048-A2 HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2012-06-07 WO disclosed
EP-2231669-A1 PHOSPHODIESTERASE INHIBITORS The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) 2010-09-29 EP disclosed
WO-2009089027-A1 PHOSPHODIESTERASE INHIBITORS GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICE, NATIONAL INSTITUTES OF HEALTH (US) 2009-07-16 WO disclosed
WO-2009012375-A2 SQUARATE KINASE INHIBITORS WYETH (US) 2009-01-22 WO disclosed
EP-1991531-A1 CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
WO-2007100880-A1 CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-09-07 WO disclosed
US-20020065309-A1 Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists AFFYMAX, INC. 2002-05-30 US disclosed
WO-2002011732-A1 NOVEL BICYCLIC AND TRICYCLIC PYRROLIDINE DERIVATIVES AS GNRH ANTAGONISTS GLAXO GROUP LIMITED (GB) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065309-A1 Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists GNRHR, FSHR, LHCGR GAA 3548/4885CYP3A4 2787/4885CYP1A2 3100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.